JP2021516049A - 組換えｔ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法 - Google Patents

組換えｔ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法 Download PDF

Info

Publication number
JP2021516049A
JP2021516049A JP2020545519A JP2020545519A JP2021516049A JP 2021516049 A JP2021516049 A JP 2021516049A JP 2020545519 A JP2020545519 A JP 2020545519A JP 2020545519 A JP2020545519 A JP 2020545519A JP 2021516049 A JP2021516049 A JP 2021516049A
Authority
JP
Japan
Prior art keywords
cell
cancer
virus
tcr
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020545519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516049A5 (https=
Inventor
ブランドン デコスキー
ブランドン デコスキー
チェン−ユ チャン
チェン−ユ チャン
Original Assignee
ザ ユニバーシティ オブ カンザス
ザ ユニバーシティ オブ カンザス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニバーシティ オブ カンザス, ザ ユニバーシティ オブ カンザス filed Critical ザ ユニバーシティ オブ カンザス
Publication of JP2021516049A publication Critical patent/JP2021516049A/ja
Publication of JP2021516049A5 publication Critical patent/JP2021516049A5/ja
Priority to JP2023212042A priority Critical patent/JP2024037917A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020545519A 2018-03-01 2019-02-27 組換えｔ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法 Pending JP2021516049A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023212042A JP2024037917A (ja) 2018-03-01 2023-12-15 組換えｔ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637240P 2018-03-01 2018-03-01
US62/637,240 2018-03-01
PCT/US2019/019754 WO2019168923A1 (en) 2018-03-01 2019-02-27 Techniques for generating cell-based therapeutics using recombinant t cell receptor genes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023212042A Division JP2024037917A (ja) 2018-03-01 2023-12-15 組換えｔ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法

Publications (2)

Publication Number Publication Date
JP2021516049A true JP2021516049A (ja) 2021-07-01
JP2021516049A5 JP2021516049A5 (https=) 2022-02-28

Family

ID=67806393

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020545519A Pending JP2021516049A (ja) 2018-03-01 2019-02-27 組換えｔ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法
JP2023212042A Pending JP2024037917A (ja) 2018-03-01 2023-12-15 組換えｔ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023212042A Pending JP2024037917A (ja) 2018-03-01 2023-12-15 組換えｔ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法

Country Status (8)

Country Link
US (2) US12178831B2 (https=)
EP (2) EP3759133A4 (https=)
JP (2) JP2021516049A (https=)
KR (1) KR20210006330A (https=)
CN (1) CN112119086A (https=)
AU (1) AU2019227700B2 (https=)
CA (1) CA3092794A1 (https=)
WO (1) WO2019168923A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017192536A1 (en) * 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
WO2021150903A1 (en) * 2020-01-22 2021-07-29 Atreca, Inc. High throughput linking of multiple transcripts
WO2022242359A1 (zh) * 2021-05-20 2022-11-24 中国科学院广州生物医药与健康研究院 一种体液免疫系统再生的方法及其应用
CN119677842A (zh) * 2022-03-17 2025-03-21 科士华(南京)生物技术有限公司 人工合成肿瘤浸润淋巴细胞
US20250216381A1 (en) * 2022-03-21 2025-07-03 Alaunos Therapeutics, Inc. Methods for Identifying Neoantigen-Reactive T Cell Receptors
WO2023237541A1 (en) * 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017053902A1 (en) * 2015-09-25 2017-03-30 Abvitro Llc High throughput process for t cell receptor target identification of natively-paired t cell receptor sequences
WO2017096239A1 (en) * 2015-12-04 2017-06-08 St. Jude Children's Research Hospital, Inc. Cloning and expression system for t-cell receptors
WO2017120428A2 (en) * 2016-01-06 2017-07-13 Health Research, Inc. Compositions and libraries comprising recombinant t-cell receptors and methods of using recombinant t-cell receptors
WO2017180738A1 (en) * 2016-04-12 2017-10-19 Medimmune, Llc Immune repertoire mining

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
IL157335A0 (en) 2001-03-13 2004-02-19 Novartis Ag Lentiviral packaging constructs
DE10132440A1 (de) 2001-07-04 2003-01-23 Bosch Gmbh Robert System und Verfahren zum Überwachen des Fahrverhaltens eines Fahrzeugs
US8709762B2 (en) * 2010-03-02 2014-04-29 Bio-Rad Laboratories, Inc. System for hot-start amplification via a multiple emulsion
US9233125B2 (en) 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
WO2013044225A1 (en) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
EP2861760B1 (en) 2012-06-15 2020-01-01 The Board of Regents of The University of Texas System High throughput sequencing of multiple transcripts of a single cell
WO2013192570A1 (en) * 2012-06-21 2013-12-27 Gigagen, Inc. System and methods for genetic analysis of mixed cell populations
CN113005091A (zh) 2013-02-06 2021-06-22 细胞基因公司 具有改进特异性的修饰的t淋巴细胞
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
RU2578009C2 (ru) * 2013-05-08 2016-03-20 Закрытое акционерное общество "ЕВРОГЕН" Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках
CN105814083A (zh) 2013-10-15 2016-07-27 加州生物医学研究所 嵌合抗原受体t细胞开关和其用途
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
US10934346B2 (en) * 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
NZ724320A (en) 2014-03-14 2022-05-27 Adaptimmune Ltd Tcr libraries
CN104091269A (zh) 2014-06-30 2014-10-08 京东方科技集团股份有限公司 一种虚拟试衣方法及虚拟试衣系统
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
CA2964958A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
HK1245827B (en) 2014-12-15 2020-06-19 Board Of Regents Of The University Of Texas System Methods for controlled activation or elimination of therapeutic cells
EP3234144B1 (en) 2014-12-15 2020-08-26 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
EP4286511A3 (en) 2015-06-12 2024-03-06 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
GB2592821B (en) * 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
MX2018003532A (es) * 2015-09-24 2019-04-25 Abvitro Llc Conjugados de afinidad-oligonucleotido y usos de los mismos.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017053902A1 (en) * 2015-09-25 2017-03-30 Abvitro Llc High throughput process for t cell receptor target identification of natively-paired t cell receptor sequences
WO2017096239A1 (en) * 2015-12-04 2017-06-08 St. Jude Children's Research Hospital, Inc. Cloning and expression system for t-cell receptors
WO2017120428A2 (en) * 2016-01-06 2017-07-13 Health Research, Inc. Compositions and libraries comprising recombinant t-cell receptors and methods of using recombinant t-cell receptors
WO2017180738A1 (en) * 2016-04-12 2017-10-19 Medimmune, Llc Immune repertoire mining

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BORIA I. ET AL., BMC IMMUNOL., vol. Vol. 9:50, JPN6024009880, 2008, ISSN: 0005279340 *
SUN X ET AL.: ""Unbiased analysis of TCRα/β chains at the single-cell level in humanCD8+ T-cell subsets."", PLOS ONE, vol. 7, no. 7, JPN6023006439, 6 July 2012 (2012-07-06), pages 40386, ISSN: 0004992724 *
TURCHANINOVA MA ET AL.: ""Pairing of T-cell receptor chainsvia emulsion PCR."", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 43, no. 9, JPN6023006437, 26 June 2013 (2013-06-26), pages 2507 - 15, ISSN: 0004992725 *

Also Published As

Publication number Publication date
EP4495246A3 (en) 2025-03-26
KR20210006330A (ko) 2021-01-18
EP3759133A4 (en) 2021-12-15
WO2019168923A1 (en) 2019-09-06
CN112119086A (zh) 2020-12-22
US12178831B2 (en) 2024-12-31
US20250154222A1 (en) 2025-05-15
AU2019227700A1 (en) 2020-10-08
US20210000873A1 (en) 2021-01-07
EP3759133A1 (en) 2021-01-06
EP4495246A2 (en) 2025-01-22
JP2024037917A (ja) 2024-03-19
CA3092794A1 (en) 2019-09-06
AU2019227700B2 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
US20240360234A1 (en) Genetically modified natural killer cells for cd70-directed cancer immunotherapy
CN112739817B (zh) 表达有嵌合受体的t细胞
US20210253726A1 (en) Car expression vector and car-expressing t cells
US20240165158A1 (en) Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
JP7245647B2 (ja) 養子細胞療法用の操作された細胞
US20250154222A1 (en) Techniques for generating cell-based therapeutics using recombinant t cell receptor genes
JP2020195393A (ja) 養子細胞療法用の操作された細胞
CN111511911B (zh) 表达特异性地识别人间皮素的细胞表面分子、il-7和ccl19的免疫活性细胞
KR20200026805A (ko) 세포 요법 및 면역조절 화합물의 조합
JP2022552314A (ja) 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用
CN112204133B (zh) Car nk细胞
US20250152717A1 (en) Binding proteins and engineered cells specific for neoantigens and uses thereof
JP2018519842A (ja) 免疫細胞の有効性および増大を改善する方法
KR20200097253A (ko) T 세포 조성물의 생산방법
US20200223899A1 (en) Braf-specific tcrs and uses thereof
KR20230010228A (ko) 자연 살해 세포를 표적으로 하는 키메라 항원 수용체 (cars)
US20230210902A1 (en) Sars-cov-2-specific t cells
KR20250114396A (ko) 부 조직적합성 항원 ha-2를 표적으로 하는 t 세포 수용체
KR20230022868A (ko) 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
US20250177531A1 (en) Binding proteins specific for ras neoantigens and uses thereof
CN114555790A (zh) Wt-1特异性t细胞免疫疗法
WO2022271637A1 (en) Method for preserving developmental potential of immune cells used for adoptive cellular therapies
US20250262242A1 (en) Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof
CN121586583A (zh) 包含并表达自噬正调节因子的经修饰人淋巴细胞
HK40073285A (en) T-cell immunotherapy specific for wt-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201209

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231215

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240110

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240315